ANA-KIN · Advancing Novel Approaches in Kinase Interface Networks

Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.

Project objective

ANA-KIN will train 12 doctoral researchers to redefine kinase drug discovery by pioneering strategies that move beyond the ATP site. Protein kinases are among the most validated drug targets, yet nearly all approved inhibitors still target the highly conserved ATP cleft, a 20-year-old paradigm that has seen remarkably little conceptual renewal. Dimerization and substrate interfaces, by contrast, are far less conserved and represent fundamentally different regulatory entry points. However, the field currently lacks the generalisable assays and cross-disciplinary integration needed to systematically exploit them.To address this, ANA-KIN establishes the first coordinated European framework dedicated to mapping and modulating kinase interfaces. It brings together leading expertise in chemical biology, structural biophysics, AI-guided design, PPI-focused discovery technologies and cellular mechanism across 12 academic laboratories and 10 academic and industrial partners. This integrated effort will produce ATP-locking chemical tools, modular interface-focused assays, high-resolution conformational maps and complementary bicyclic peptide/small-molecule discovery engines that collectively enable the systematic identification of interface-selective modulators.The training programme couples interdisciplinary co-supervision, intersectoral secondments and network-wide scientific schools with structured development in scientific, transferable, open-science and entrepreneurial skills. Robust governance (Supervision Oversight Board and Ombudsperson) ensures transparent supervision, while diversity and culture-of-care measures foster an inclusive and supportive environment.Through this coordinated research and training ecosystem, ANA-KIN will generate the tools, mechanistic foundations and interdisciplinary expertise required to unlock kinase interfaces as a new therapeutic frontier, while preparing a cohort capable of driving next-generation kinase drug discovery in Europe

Original text from CORDIS.

Participants

• ARISTOTELIO PANEPISTIMIO THESSALONIKIS · THESSALONIKICoordinatorGreece
• ASTRAZENECA UK LIMITED · CAMBRIDGEUnited Kingdom
• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS · ParisFrance
• ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE · LausanneSwitzerland
• ENZYQUEST PRIVATE COMPANY · HERAKLIONGreece
• INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE · ParisFrance
• JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN · Frankfurt Am MainGermany
• KATHOLIEKE UNIVERSITEIT LEUVEN · LeuvenBelgium
• NORTHEASTERN UNIVERSITY · Boston MaUnited States
• NOVARTIS PHARMA AG · BaselSwitzerland
• PANEPISTIMIO KRITIS · RETHIMNOGreece
• SERVIER GYOGYASZATI VEGYTANI KUTATOINTEZET ZARTKORUEN MUKODO RESZVENYTARSASAG · BudapestHungary
• Skylight Therapeutics BV · LeuvenCity levelBelgium
• THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD · OxfordUnited Kingdom
• THE SCRIPPS RESEARCH INSTITUTE CORPORATION · LA JOLLAUnited States
• UNIVERSIDAD POMPEU FABRA · BarcelonaSpain
• UNIVERSITAT DES SAARLANDES · SaarbruckenGermany
• UNIVERSITE D'AIX MARSEILLE · MarseilleFrance
• UNIVERSITEIT LEIDEN · LeidenNetherlands
• VIB VZW · ZWIJNAARDE - GENTBelgium

Links

• View on CORDIS
• DOI: 10.3030/101312304